Abstract
α-Adrenoceptor antagonists have been used clinically for over 25 years. While a few of the compounds in use today (so-called 'third-generation' α-blockers such as doxazosin) share common features with their earlier counterparts ('first-' and 'second-generation' α-blockers), refinements in their pharmacology have resulted in important clinical differences. Studies with doxazosin have demonstrated efficacy and tolerability in hypertension and benign prostatic hyperplasia (BPH) in younger and older subgroups of patients, and in patients with associated risk factors for cardiovascular disease. The once-daily dosing regimen is convenient for the majority of patients and, thus, aids compliance. Given that many patients with BPH will be older, may have high blood pressure or other risk factors for cardiovascular disease, and may be taking one or more medications for concurrent illness, doxazosin offers a unique approach to the management of disease - BPH and beyond.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
